DUBAI, UNITED ARAB EMIRATES–(Marketwire – October 17, 2010) – Today at Gitex 2010, Imprivata^®, Inc., the company that simplifies and secures user access, and Secureway, the leader in IT Security Market Value Added Distribution in the Middle East and Africa, announced that they are partnering to address the growing workflow and security challenges faced by companies, hospitals and government organizations in the region. Their combined technology leadership, broad reach and superior services are helping customers to strengthen user authentication, streamline application access and simplify compliance reporting. 

“Our decision to partner with Imprivata is a testament to the quality of the OneSign platform,” commented Fari Boustantchi, CEO at Secureway. “Secureway has a reputation for adding value in the Middle East and Africa by carefully selecting only market leading technologies for the comprehensive IT security solutions that we deliver. Imprivata OneSign’s clear leadership in the authentication and access management space makes it a perfect complement for our portfolio.”

In its recently published “MarketScope for Enterprise Single Sign-on,”¹ Gartner rated Imprivata as Strong Positive, the highest possible Marketscope rating. Imprivata has fortified its enterprise single sign-on (ESSO) market leadership position by delivering innovative capabilities, adding customers at an impressive rate, and engaging in key partnerships over the past year. Gartner advises current customers of vendors rated as Strong Positive to continue with planned investments, and potential customers to consider a vendor in this category as a strong choice for strategic investments. A copy of the report can be found here.

“The need to secure data, comply with government regulations and improve user productivity has presented a tremendous opportunity for Imprivata in North America and Europe,” said Omar Hussain, president and CEO at Imprivata. “We have become the trusted advisor to more than 1,000 customers and now the time is right for Imprivata to bring OneSign to the Middle East. With Secureway’s understanding of the local markets, solid IT security background and breadth of reach we are looking forward to extending our success by solving these same issues for customers in this region.”

See Imprivata OneSign in the Secureway stand at Gitex 2010, September 17-21

Secureway stand Z-M1 in Za’beel Hall

Dubai International Convention and Exhibition Centre

Centrally managed from a single administrative console, Imprivata OneSign secures access across Windows, host-based, Citrix and virtual desktop environments. OneSign empowers organizations to balance the need for stronger security with improved user workflow and productivity. The solution also reduces the time and complexity of complying with regulated access control requirements and password management costs that consume IT help desk resources. Key Imprivata OneSign features include One-Touch “Follow Me” Desktops, Automatic Desktop Locking, Enhanced Transaction-level Authentication, Walk-Away Security for Unattended Desktops, Shared Workstations and Fast User Switching, built-in support for a broad range of authentication and multiple card types, Self-Service Password Reset and seamless integration with context management solutions.

About Imprivata
Imprivata is the leading independent vendor focused on simplifying and securing user access. By strengthening user authentication, streamlining application access and simplifying compliance reporting across multiple computing environments, customers realize substantial IT helpdesk and administration cost savings, while achieving the security standards they demand.

Imprivata has received numerous product awards and top review ratings from leading industry publications and analysts, including a Strong Positive rating in Gartner’s 2010 ESSO Marketscope. Headquartered in Lexington, Mass., Imprivata partners with over 200 resellers, and serves the access security needs of more than 1,000 customers around the world. For more information, please visit www.imprivata.com.

About Secureway
Secureway Network Distributors are the Middle East’s Specialist Value Added Distributors in the IT Security & Mobility Industry. Secureway Network Distributors offers Middle East Value Added Resellers an excellent opportunity to capitalize on their growing customer bases by providing End to End IT security solutions, while assisting them in the full lifecycle of the project. With focus on pure Value-Added Distribution, Secureway Network Distributors has the global backup and local experience to deliver an unparalleled level of service, support, logistics and competitive pricing to the Middle East IT marketplace.

Secureway brings market leaders to the Middle East region. Our vendors are all leaders in their domain, usually with no solid presence in the region. We keep a constant eye on technology leaders in specialist security markets and add them to our portfolio, this also encompasses adding new IT security start-up vendors, and these new vendors with their unique technology are the stars of tomorrow. We do keep our vendor portfolio limited to enable focused manageability.

Imprivata is a registered trademark of Imprivata, Inc. in the USA and other countries. All Imprivata products are trademarks of Imprivata, Inc. in the USA and other countries.

RSS Feed to Imprivata News: http://feeds.feedburner.com/ImprivataNews
Follow Imprivata on Twitter: https://twitter.com/Imprivata

¹ Gartner, Inc., “MarketScope for Enterprise Single Sign-On” by G. Kreizman. September 2010

id=”nav_links”>

CHICAGO, IL–(Marketwire – October 16, 2010) –  AAO Booth #1408 — Carl Zeiss Meditec today unveiled its newest product innovations at the 2010 American Academy of Ophthalmology annual meeting in Chicago. Powered by the FORUM Ophthalmic Data Management System, the new Glaucoma Workplace features FORUM HFA-Cirrus Combined Report (CR™), the world’s first commercially available OCT and visual field integration. In addition, new FDA-cleared products commercially available for the first time in the United States will be on display during the exhibition.

The FORUM Glaucoma Workplace

As part of Carl Zeiss Meditec’s ‘Creating What’s to Come’ theme, the FORUM Glaucoma Workplace delivers essential diagnostic technologies, such as perimetry, spectral domain OCT, fundus photography and scanning laser polarimetry, for unprecedented clinical utility and paperless workflow.

The FORUM Glaucoma Workplace adds a new diagnostic assessment feature — HFA-Cirrus Combined Report — the industry’s first integration of OCT and visual field diagnostic analysis. By combining data from the gold-standard Humphrey^® Field Analyzer (HFA™) and Cirrus™ HD-OCT, this FORUM Combined Report provides structure and function status at-a-glance to help doctors make time-saving clinical assessments. This one-page digital snapshot delivers key patient exam information at the point-of-care for both right and left eyes of visual function, RNFL and optic nerve analysis.

“Clinical assessment of glaucoma patients, or particularly patients who have suspect glaucoma, requires assessment of visual function test results and structural parameters comparing both diagnostic modalities in each eye,” said Anders Heijl, MD, PhD, Professor and Chairman, Department of Ophthalmology, University of Lund, Sweden. “Automatically providing structural OCT and visual field data in a single combined on-screen report will save time and facilitate such comparisons. This type of development is important for the quality of clinical decision-making in routine glaucoma care.”

“FORUM’s Glaucoma Workplace and the new HFA-Cirrus Combined Report is a big step forward, and I am excited about the potential of this unique new capability,” said Michael S. Jacobs, MD, of Athens Eye Associates, Athens, GA. “Having OCT and perimetry data available in a single format will allow me to perform a more focused exam and ultimately to spend more time making the decisions that only I can make.”

With an estimated 25,000 Humphrey Field Analyzer II-i perimetry systems and approximately 6,000 Cirrus HD-OCT platforms in use worldwide, Carl Zeiss Meditec customers with both platforms can seamlessly integrate FORUM Glaucoma Workplace and the Combined Report into their practice. In addition, key ZEISS diagnostic instruments sold today are FORUM ready and include DICOM Gateway software and a DICOM Gateway license.*

New FDA-Cleared Products

Also being introduced at this year’s AAO meeting is the VISULAS 532s VITE photocoagulator which recently received marketing clearance from the U.S. Food and Drug Administration (FDA). The new keratoplasty indication for the VisuMax^® Femtosecond Laser has also been granted FDA clearance, which is expected to significantly expand the product’s treatment range. 

• VISULAS 532s VITE — This unique photocoagulation laser features variable and interactive multi-spot treatment cascades, giving ophthalmologists the greatest choice of treatment options to enhance therapeutic workflow and patient comfort during retinal photocoagulation procedures. Based on the concept of flexible treatment multi-spot cascades, linear, circular and customized coagulation strategies can be pursued in addition to traditional single-spot photocoagulation.

• Keratoplasty Application for the VisuMax^® Femtosecond Laser — The VisuMax Femtosecond Laser has received clearance from the U.S. FDA to perform lamellar resection of the cornea, lamellar keratoplasty, penetrating keratoplasty and corneal harvesting procedures. With a fast repetition rate of 500 kHz, the VisuMax delivers highly reproducible incisions with optimized surgical workflow.

“We are pleased to deliver a new suite of innovations that represents our philosophy of ‘Creating What’s to Come’ at this year’s AAO meeting,” said Ludwin Monz, CEO of Carl Zeiss Meditec. “Evolving from the FORUM Ophthalmic Data Management System that we introduced just one year ago, we now offer the Glaucoma Workplace and FORUM Combined Report, each of which will deliver time-saving and workflow advantages to ophthalmic practices worldwide. In addition, we are pleased to introduce new FDA-cleared therapeutic lasers that span refractive and retina treatment capabilities, reinforcing our commitment to continually advance our integrated product offerings for the benefit of our customers and their patients.” 

The FORUM Glaucoma Workplace and new FDA-cleared products will be on display at Carl Zeiss Meditec’s booth #1408 at McCormick Place in Chicago, IL. In addition, meeting delegates are invited to attend the Company-sponsored evening event, “A Vision For Your Future…Today” on Saturday, October 16, 2010 at the River East Art Center. Dual education symposia: “OCT Breakfast Conference with the Experts,” and the “Innovations in Refractive and Corneal Surgery,” will be held for meeting delegates on Sunday morning, October 17, 2010 at the Palmer House Hilton Hotel.

Brief profile
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies.

The Company supplies innovative technologies and application-oriented solutions which enable doctors to improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat ophthalmic diseases. In the field of Neuro/ENT surgery, the Company provides innovative visualization solutions. Carl Zeiss Meditec’s medical technology portfolio is rounded off by promising future technologies such as intraoperative radiotherapy.

The Company’s approximately 2,100 employees generated revenue of about EUR 600 million in fiscal year 2007/08 (ended Sept. 30). The headquarters of Carl Zeiss Meditec are located in Jena, Germany. In addition to other subsidiaries in Germany, the Company is represented by over 50 percent of its employees at sites in the USA, Japan, Spain and France.

Thirty-five percent of Carl Zeiss Meditec’s shares are in free float. The remaining 65 percent are held by Carl Zeiss AG, one of the world’s leading groups engaged in the optical and opto-electronics industry. The five independently run business segments of Carl Zeiss AG operate in the future-oriented markets “Medical and Research Solutions,” “Industrial Solutions” and “Lifestyle Products.” Carl Zeiss AG is headquartered in Oberkochen, Germany. During fiscal year 2007/08 (ended Sept. 30) the Company generated revenues of about EUR 2.7 billion. Carl Zeiss has around 13,000 employees in more than 30 countries, including more than 8,000 in Germany.

For further information please visit our website at: www.meditec.zeiss.com

* FORUM-Ready is not available for FDT and Matrix.

Click here to see all recent news from this company

CHICAGO, IL–(Marketwire – October 15, 2010) –   As Chicago’s premier dance company, the Joffrey Ballet kicks off its 2010/2011 season this week, the man in charge of keeping the dancers healthy and meeting any medical needs that may arise is Craig Westin, M.D., of Illinois Bone and Joint Institute and the Chicago Center for Orthopedics (CCO) at Weiss Hospital. Named troupe physician and CCO orthopedic surgeon for the Joffrey Ballet this year, Dr. Westin brings more than 26 years of experience working with professional performers and athletes to the dancers’ care. Whether pre-season physician examinations, regular clinics with the dancers at the Joffrey studios, or an emergency consultation at Weiss Hospital, these healthcare services are an essential part of a successful dance season.

As an orthopedic resident at Harvard, Dr. Westin began treating dancers when he helped cover the Boston Ballet. He continued with Ballet West in Salt Lake City, where he also served as medical director of the Snowbird Ski Clinic. After 17 years at Snowbird and the 2002 Winter Olympics in Salt Lake City, Dr. Westin moved to Chicago. Over the past 15 years, Dr. Westin has been a physician to the U.S. and Olympic Figure Skating team and traveled with them to Europe, China and Russia. He is also the personal orthopedic surgeon for Olympic Figure Skating Silver Medalist Sasha Cohen. Specializing in sports medicine with a particular focus on the knee and shoulder, Dr. Westin uses minimally invasive arthroscopic techniques for outpatient knee and shoulder repairs. As well as being a certified Carticel surgeon for cartilage repair and restoration, he has special expertise in reconstruction of ACL tears and kneecap problems.

Dr. Westin uses many non-operative treatments to help his patients recover. Treatments like physical therapy, injections, braces, orthotics and other rehabilitation techniques can provide dramatic improvement for many conditions. “What we learn from treating these gifted and highly motivated performers can often be applied to the rest of us. We all have the same body parts, they can just use theirs a lot better,” says Westin.

“I’m honored to be named the sports medicine physician for the Joffrey Ballet. I have a deep appreciation for these athletes’ need for top care and am pleased that I can play a role in keeping them healthy and performing. It’s very satisfying to see them on stage able to use their bodies for inspiring expression,” added Dr. Westin.

The Sports Medicine Experts at Weiss
CCO orthopedic surgeons and sports medicine physicians — with affiliations at Chicago’s academic and research facilities, including the University of Chicago, the University of Illinois and Loyola University Chicago — treat Joffrey Ballet dancers and other athletes to ensure their long-term health and viability on and off the stage or athletic fields. CCO brings a balance of preventive care, individual athlete/patient understanding and leading-edge techniques.

ST. CHARLES, IL–(Marketwire – October 15, 2010) –  At a time when budgets are being cut, costs scrutinized and improvements deferred, members of the St. Charles Country Club recently banded together to bring accuracy improving technology to their local community women’s health center. 

In a golf and tennis outing this summer, St. Charles Country Club members Christine Kluck, Sue Dugan, Sara Woods and Mary Lisa Vale organized 70+ members to help buy a Magnification Localization Paddle Kit for the Delnor Center for Breast Health. The Magnification Localization Paddle is a device which provides greater visual accuracy, clarity and detail during localization of suspicious lesions or calcifications in the breast. As a result, patients may have less tissue removed, heal quicker and have improved accuracy for a more positive outcome, both physically and mentally.

According to Teri Koehn, Manager of the Women’s Imaging at the Delnor Center for Breast Health, “It is both humbling and refreshing to have members of the community participate in the purchase of equipment for us and our patients. The efforts of the women at the St. Charles Country Club will have a big impact on the high level of care we provide to our patients, particularly at a time when costs are rising and spending heavily scrutinized.” 

The Delnor Center for Breast Health located in Geneva, Illinois, promotes breast wellness by providing excellence in screening and diagnostic services for the Fox Valley community. The Center, which specializes in women’s needs, performs five-to-six breast localizations each week. The new Magnification Localization Paddle Kit, already in operation, is being used by radiologists and technicians for improved accuracy. 

Additionally, through the highly successful efforts of the St. Charles Country Club’s fund raising initiative, the Center was able to purchase 150 issues of the Breast Cancer Treatment Handbook, by Judy C. Kneece, RN, OCN which it will distribute to breast cancer patients. The handbook provides comprehensive insights on the technical and medical aspects of treatments and the emotional challenges faced by women undergoing breast cancer treatment.

Organizer Christine Kluck says, “Working with co-members of the St. Charles Country Club, its staff and the Delnor Center for Breast Health has been a most rewarding and personally satisfying experience. The women of the Club were eager to join the effort to assure all the women in our Fox Valley community have local access to advanced imaging technology that can help them avoid painful biopsies, uncomfortable recoveries and the emotional stress of waiting for results.”

About St. Charles Country Club

The St. Charles Country Club, located in west-suburban Chicago, is a perfect retreat for those seeking camaraderie, competition, relaxation, family fun and a high level of personal service. Founded in 1924, the Club is nestled on 270 acres in the scenic Fox River Valley. Its original golf course, which has been periodically updated and expanded, was designed by world-renowned Tom Bendelow. In addition to the unique and challenging Quarry Course, members enjoy the amenities of a 34,000 square-foot Clubhouse, two swimming pools, a Tennis Center, day camp, full-swing driving range, expansive putting greens and world-class banquet facilities. The St. Charles Country Club and its membership are dedicated to being active and involved neighbors through their participation in and support of programs and activities that benefit their community. 

About Delnor Center for Breast Health

The Center for Breast Health promotes breast wellness by providing excellence in screening and diagnostic services for the Fox Valley community. The Center for Breast Health staff is dedicated to providing prompt, private, personal and compassionate care in an atmosphere that has been designed for women. It offers an exceptional team of skilled mammography and ultrasound technicians, radiologists, pathologists, oncologists, surgeons, plastic surgeons and nurses. Delnor also has an active clinical trial program. The Center for Breast Health is located at 351 Delnor Drive, Suite 201, on the Delnor hospital campus. To schedule an appointment, call (630) 762-6400.

Click here to see all recent news from this company

CHICAGO, IL–(Marketwire – October 15, 2010) –  Ziegler (PINKSHEETS: ZGCO), a specialty investment bank serving the healthcare, senior living, religion, and education sectors, achieved a $1 billion milestone for underwritings in the senior living sector. Nationally, Ziegler is ranked as one of the leading investment banking firms in senior living finance issues.

With the recent closing of the Total Longterm Care transaction, a financing to refund existing debt and finance new construction for the nation’s second largest Program of All-inclusive Care for the Elderly (PACE), Ziegler has successfully closed 17 senior living transactions totaling $1 billion this year. Ziegler tailors its products and services to accommodate the most complex financings for virtually every type of non-profit senior living provider.

Dan Hermann, Senior Managing Director and Head of Investment Banking, commented, “Ziegler is committed to delivering comprehensive financial services to senior living providers, retirement communities, and CCRCs. We are extremely proud of this milestone — an important accomplishment by our firm on behalf of the senior living community.” The milestone is particularly significant given Ziegler’s 2009 experience, when it completed over $900 million during the months following the ‘thawing’ of the capital markets post-economic crisis.

For more information about Ziegler, and its mission of advancing health, wealth and well-being through tailored financial solutions, please visit us at www.Ziegler.com.

About Ziegler:

The Ziegler Companies, Inc. (PINKSHEETS: ZGCO) together with its affiliates (Ziegler) is a specialty investment bank with unique expertise in complex credit structures and advisory services. Nationally, Ziegler is ranked as one of the leading investment banking firms in its specialty sectors of healthcare, senior living, religion and education finance, as well as corporate finance and FHA/HUD. Headquartered in Chicago, IL with regional and branch offices throughout the U.S., Ziegler creates tailored financial solutions including bond financing, advisory, private placement, seed capital, M&A, risk and asset management. Ziegler serves institutional and individual investors through its wealth management and capital markets distribution channels.

Certain comments in this news release represent forward-looking statements made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are subject to a number of risks and uncertainties, in particular, the overall financial health of the securities industry, the strength of the healthcare sector of the U.S. economy and the municipal securities marketplace, the ability of the Company to underwrite and distribute securities, the market value of mutual fund portfolios and separate account portfolios advised by the Company, the volume of sales by its retail brokers, the outcome of pending litigation, and the ability to attract and retain qualified employees.

MADISON, WI–(Marketwire – October 15, 2010) – TomoTherapy Incorporated (NASDAQ: TOMO) announced today that it will host an analyst and investor presentation in conjunction with the annual ASTRO (American Society for Radiation Oncology) meeting in San Diego, Calif., on Monday, November 1, 2010, at 8:00 a.m. PDT.

Analysts and institutional investors are invited to register for this event by visiting: http://www.tomotherapy.com/register/2010_astro_analyst_investor_presentation.
Space is limited and early registration is advised.

TomoTherapy’s management team will present an update on its business and highlights of new developments for the TomoTherapy^® radiation therapy platform. The company’s presentation will be Webcast. To access the live Webcast on November 1, 2010, go to the Investor Relations page of TomoTherapy.com and click on the Webcast icon. A replay of the Webcast will be available beginning at 11:00 a.m. PDT on the same day.

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art^® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries

MARKHAM, ONTARIO–(Marketwire – Oct. 15, 2010) – Extendicare Real Estate Investment Trust (“Extendicare REIT” or the “REIT”) (TSX:EXE.UN) today announced that it has declared a cash distribution of C$0.07 per unit of the REIT (the “REIT Units”) for the month of October 2010, which is payable to unitholders of record at the close of business on October 29, 2010, and will be paid on November 15, 2010.

Extendicare Limited Partnership (the “Partnership”) also announced that it has declared a cash distribution of C$0.07 per Class B limited partnership unit (the “Exchangeable LP Units”) for the month of October 2010, which is payable to unitholders of record at the close of business on October 29, 2010, and will be paid on November 15, 2010.

The current annualized distribution rate of the REIT and Partnership is C$0.84 per unit, payable in monthly distributions of C$0.07 per unit. In accordance with the distribution policy of both the REIT and the Partnership, unitholders of record at the close of business on the last business day of each calendar month will be paid a distribution on or about the 15^th day of the following month.

Management estimates that approximately 70% of the 2010 distributions of the REIT and Partnership will be characterized as tax-deferred returns of capital for Canadian residents. To the extent the remaining 30% of distributions of the REIT and Extendicare LP to be made in 2010 are taxed as dividends, those paid to Canadian residents are eligible dividends as per the Income Tax Act (Canada). The REIT is not required to, and does not, calculate its “earnings and profits” pursuant to the United States Internal Revenue Code of 1986, as amended, and therefore no portion of its distributions represent qualified dividend income for U.S. tax purposes.

The REIT has a Distribution Reinvestment Plan, which provides Canadian resident holders of REIT Units and Exchangeable LP Units with the opportunity to increase their respective investments at a 3% discount to the volume weighted average trading price of the REIT Units on the TSX for the five trading days immediately preceding the distribution payment date. A copy of the Plan package is available under the investors section of the REIT’s website.

About Us

Extendicare REIT is a leading North American provider of long-term and short-term senior care services through its network of owned and operated health care centers. We employ 37,800 qualified and experienced individuals dedicated to helping people live better through a commitment to quality service that includes post-acute care, rehabilitative therapies and home health care services. Our 263 senior care centers in North America have capacity for approximately 29,200 residents. Extendicare REIT is a specified investment flow-through trust (SIFT) that has been subject to the SIFT tax since January 1, 2007.

Forward-looking Statements

Information provided by Extendicare REIT from time to time, including this release, contains or may contain forward-looking statements concerning anticipated financial events, results, circumstances, economic performance or expectations with respect to the REIT and its subsidiaries, including its business operations, business strategy, and financial condition. Forward-looking statements can be identified because they generally contain the words “expect”, “intend”, “anticipate”, “believe”, “estimate”, “project”, “plan” or “objective” or other similar expressions or the negative thereof. Forward-looking statements reflect management’s beliefs and assumptions and are based on information currently available, and the REIT assumes no obligation to update or revise any forward-looking statement, except as required by applicable securities laws. These statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the REIT to differ materially from those expressed or implied in the statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on the REIT’s forward-looking statements. Further information can be found in the disclosure documents filed by Extendicare REIT with the securities regulatory authorities, available at www.sedar.com and on the REIT’s website at www.extendicare.com.

IRVINE, CA–(Marketwire – October 14, 2010) – Sun Healthcare Group, Inc. (NASDAQ: SUNH) invites investors to listen to a conference call with Sun’s senior management on Thursday, Oct. 28, 2010, at 10 a.m. Pacific / 1 p.m. Eastern to discuss the Company’s earnings for the third quarter of 2010.

To listen to the conference call, dial (888) 437-9364 and refer to Sun Healthcare Group. A recording of the call will be available from 4 p.m. Eastern on Oct. 28, 2010, until midnight Eastern on Nov. 28, 2010, by calling (888) 203-1112 and using access code 4118106.

About Sun Healthcare Group, Inc.

Sun’s subsidiaries provide nursing, rehabilitative and related specialty healthcare services principally to the senior population in the United States. Sun’s core business is providing, through its subsidiaries, inpatient services, primarily through 166 skilled nursing centers, 16 combined skilled nursing, assisted and independent living centers, 10 assisted living centers, two independent living centers and eight mental health centers. On a consolidated basis, Sun has annual revenues of $1.9 billion and approximately 30,000 employees in 46 states. At June 30, 2010, SunBridge centers had 23,209 licensed beds located in 25 states, of which 22,427 were available for occupancy. Sun also provides rehabilitation therapy services to affiliated and non-affiliated centers through its SunDance subsidiary, medical staffing services through its CareerStaff Unlimited subsidiary and hospice services through its SolAmor subsidiary.

In May 2010, Sun announced a plan to restructure its business by separating its real estate assets and its operating assets into two separate publicly traded companies through a series of internal restructurings (the “Restructuring”), subject to the approval of stockholders and other conditions. In connection with the Restructuring, SHG will own and continue to operate all of Sun’s operating subsidiaries, with stockholders of Sun receiving a pro rata distribution of the stock of SHG (the “Separation”). Substantially all of Sun’s currently-owned real estate assets will be owned by Sabra Health Care REIT, Inc., a subsidiary of Sun (“Sabra”) and, immediately after the Separation, Sun will merge into Sabra. Following this merger, SHG will change its name to Sun Healthcare Group, Inc. The common stock of both companies is expected to trade on the NASDAQ Global Select Market. The Restructuring (including the Separation) is expected to be completed in the fourth quarter of 2010.

PORTSMOUTH, NH–(Marketwire – October 14, 2010) –  NitroSecurity, Inc., the leader in high-performance, content-aware security information and event management solutions (SIEM), today announced that Roswell Park Cancer Institute (RPCI) has selected the company’s integrated NitroView SIEM, log management and database monitoring solutions.

Founded in 1898, RPCI is the nation’s first cancer center, and the only upstate New York facility to hold the National Cancer Institute (NCI) designation of “comprehensive cancer center.” Accommodating approximately 200,000 outpatient visits annually, RPCI is a member of the prestigious National Comprehensive Cancer Network (NCCN). Its computing infrastructure comprises approximately 300 servers, 5,000 PCs and a host of tablets and smartphones.

For any healthcare organization, the security of personal health information (PHI) is of the highest priority. IT leadership at RPCI found that despite the Institute’s comprehensive infrastructure, security event and log information was not as rapidly discoverable and actionable as they desired — that data was often spread across disparate and disconnected systems. To remedy this, RPCI conducted an extensive search for a SIEM solution that would address those issues. The goal was to achieve greater visibility into and across data silos to more effectively and efficiently identify potential risks to PHI security.

“RPCI is a leader in cancer research, and leveraging innovative technology helps us achieve our mission: to understand, prevent and cure cancer,” said Edward Pardo, Senior IT Security Engineer at RPCI.

“e-Healthcare initiatives like electronic health records (EHR) and the relentlessly evolving cyberthreat landscape are accelerating the growth of both data and risk,” said Ken Levine, CEO of NitroSecurity. “Just as in the diagnosis of a patient, the ability to act rapidly based on comprehensive information is critical. That’s why marquee healthcare organizations around the country like RPCI have looked to partner with NitroSecurity more than any other SIEM vendor. We provide them with the greatest ability to secure their network environment and meet the letter of the law, without being distracted from their primary mission of saving lives.”

For more information on NitroView and other NitroSecurity offerings, please visit the company’s Web site at http://www.nitrosecurity.com.

About Roswell Park Cancer Institute
The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. RPCI, founded in 1898, was one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit RPCI’s website at http://www.roswellpark.org, call 1-877-ASK-RPCI (1-877-275-7724) or email [email protected].

About NitroSecurity
NitroSecurity develops high-performance security information and event management (SIEM) solutions that protect critical information and infrastructure. NitroSecurity solutions reduce risk exposure and increase network and information availability by removing the scalability and performance limitations of security information management. Utilizing the industry’s fastest analytical tools, NitroSecurity identifies, correlates and remediates threats in minutes instead of hours, allowing organizations to quickly mitigate risks to their information and infrastructure. NitroSecurity serves more than 500 organizations in the energy, healthcare, education, financial services, government, retail, hospitality and managed services industries. For more information, please visit http://www.nitrosecurity.com.

Click here to see all recent news from this company

SAN DIEGO, CA–(Marketwire – October 14, 2010) –  Southern California is in for a real treat. Pacific Liposculpture, Inc. has officially opened the doors to their new premier lipo clinic in the UTC area. Specializing specifically in minimally invasive liposculpture procedures, Pacific Lipo is the premier practice for San Diegans’ liposuction needs.

No longer a taboo or dangerous surgery, liposculpture procedures are routine and performed to remove unwanted fat with minimal discomfort and little to no downtime. Patients do not have to undergo the dangers of general anesthesia, there are no stitches required and you can go back to work the next day.

FDA approved and safer than standard liposuction, Pacific Lipo provides instant results and fat cells are removed permanently. Pacific Lipo uses the most technologically advanced medical techniques and skilled professionals, having performed over 10,000 procedures — liposculpture is all they do and thus makes them the most experienced and best at what they do. Affordable with prices starting at just $895 per area, and free consultations available 7 days a week. For more information on liposculpture services or Pacific Lipo please contact Rodney Davis, Physician Assistant at (858) 794-LIPO or visit www.pacificlipo.com

Click here to see all recent news from this company

GAITHERSBURG, MD–(Marketwire – October 14, 2010) –  Microlog Corporation (PINKSHEETS: MLOG), a Gaithersburg, Maryland-based technology leader in Integrated Voice Response (IVR) and Computer Telephony Integration (CTI) solutions for the Government, Healthcare and Lotteries has been awarded a contract from Moncrief Army Community Hospital, the main medical center at Ft. Jackson in Columbia, South Carolina, for its Wellness Management Suite™ software application and to increase system capacity of the already installed ServiceFirst™ Contact Center. 

“We look forward to providing Moncrief Army Community Hospital with upgrades to our existing products while also installing one of our newest Microlog products,” said Microlog CEO Richard Meccarielli. “We are confident our Wellness Management Suite™ will promote health and wellness at medical facilities and also enable staff to more efficiently keep up with Healthcare Effectiveness and Information Set (HEDIS) information, which has been a troubling issue for many health centers.”

The Wellness Management Suite™ automatically sorts HEDIS data and develops a call list for each health campaign (Diabetes, Colon Cancer, PAP, Mammogram, etc.) to notify patients of wellness appointments needed. The WMS™ application is then prompted to call patients, their identity is verified, and the patient records responses whether or not they would like to set appointments. Data of those requesting appointments is then sent to hospital staff so that they can more efficiently keep track of each patient’s HEDIS record.

Along with the addition of the Wellness Management Suite™, Microlog upgraded the system hardware for their ServiceFirst™ Contact Center to increase system capacity and allow for greater call flow and less downtime for outside callers. 

About Microlog:

Microlog Corporation designs, implements and services patented software applications that enhance the productivity of the customer contact center experience, as well as providing consultation on a variety of system integration options. The company’s services encompass the migration of e-commerce into the traditional call center environment by Web enablement. Microlog’s award winning products support this Web enablement, as well as supporting all inbound and outbound media, telephone, e-mail, fax, and Web for contact centers.

For further information about Microlog’s products and solutions, please contact Vanessa Meccarielli, Investor Relations, at (202) 746-7776 or by email at [email protected].

Click here to see all recent news from this company

WINNIPEG, MANITOBA–(Marketwire – Oct. 14, 2010) – DiaMedica Inc., (TSX VENTURE:DMA) is pleased to announce positive final results from its previously announced type 1 diabetes study.

The study was designed to observe the potential protective and/or regenerative effects on beta cells (cells from the pancreas that produce insulin) in a widely accepted type 1 diabetes animal model. DiaMedica, in consultation with Dr. Maureen Gannon at Vanderbilt University, has confirmed that DM-99 can increase new beta cells by 1,277% (p<0.01) when administered to diseased animals compared to untreated diseased animals. Beta cell proliferation induced by DM-99 trended to be even greater than replication in non-diseased, untreated control animals.

The increased beta cell proliferation led to physiologically important improvements in the diabetic state. Improvements included the restoration of peak levels of plasma insulin to near normal levels (p<0.05) with positive trends of increase in the levels of both pancreatic and plasma insulin, which led to improved blood glucose clearance in a oral glucose tolerance test with DM-99 treatment. On July 8^th, DiaMedica reported initial results of the study that included a 68% reduction in fasting blood glucose (p<0.05) with DM-99.

“These results are very provocative and would indicate that this compound offers both a level of protection of beta cells in a type 1 diabetes animal model as well as induces their proliferation,” stated Dr. Maureen Gannon, Associate professor of Medicine at Vanderbilt University, Division of Diabetes, Endocrinology and Metabolism. “Having a therapeutic compound that can either protect or proliferate beta cells is a key requirement for finding a cure for type 1 diabetes so that therapies involved in replacing or regenerating these cells can work long-term. DM-99 appears to be able to perform both of these functions.”

“The ability of DM-99 to significantly increase beta cell replication combined with our earlier data showing the ability of DM-99 to protect against a variety of autoimmune attacks may result in a first in class treatment for type I diabetes”, stated Mr. Rick Pauls, President and CEO of DiaMedica. “We are currently developing DM-199, a novel recombinant and humanized form of DM-99 for commercialization.”

About DiaMedica

DiaMedica is a biopharmaceutical company focused on developing drugs with the potential to be broadly applicable in treating large unmet diseases including diabetes, autoimmune disorders and neurological diseases by protecting and proliferating a variety of cells. Two of DiaMedica’s products have demonstrated human efficacy in lowering blood sugar levels in people diagnosed with Type 2 diabetes with an excellent safety profile. DiaMedica is listed on the TSX Venture Exchange under the trading symbol “DMA”.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, the “forward-looking statements“). These forward-looking statements relate to, among other things, DiaMedica’s objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, and can, in some cases, be identified by the use of words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Specifically, this press release contains forward-looking statements regarding matters such as, but not limited to, the anticipated use of proceeds from the Offering, management’s assessment of DiaMedica’s future plans, information with respect to the advancement of DiaMedica’s research and development programs, and DiaMedica’s other estimates and expectations. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: uncertainties and risks related to our research and development programs, the availability of additional financing, risks and uncertainties relating to the anticipated use of proceeds, changes in debt and equity markets, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, the cost and supply of raw materials, management of growth, effects of insurers’ willingness to pay for products, risks related to regulatory matters and risks related to intellectual property matters.

Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release, as well as under the heading “Risk Factors” contained in DiaMedica’s 2009 annual information form. DiaMedica cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on DiaMedica’s forward-looking statements to make decisions with respect to DiaMedica, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Such forward-looking statements are based on a number of estimates and assumptions, which may prove to be incorrect, including, but not limited to, assumptions regarding the availability of additional financing for research and development companies, and general business and economic conditions. These risks and uncertainties should be considered carefully and investors and others should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, DiaMedica cannot provide assurance that actual results will be consistent with these forward-looking statements. DiaMedica undertakes no obligation to update or revise any forward-looking statement.

FALLS CHURCH, VA–(Marketwire – October 14, 2010) – Accredited Standards Committee X12 announces the release of a collection of XML schemas supporting the content mandated under the Health Insurance Portability and Accountability Act (HIPAA). The schemas are generated from the same database used to publish the HIPAA mandated ASC X12 Technical Reports.

Over the past several years organizations have created proprietary XML schemas based on the generic ASC X12 standards and associated implementation guides. Some of those schemas are sold as part of vendor applications, some are freely distributed, and many are internal to an organization. None represent official derivatives of the associated ASC X12 work products. All implementers will benefit by replacing these separate, uncoordinated initiatives with standardized XML schemas from the recognized authority. This schema production approach ensures that every structure and all data elements can be represented in an XML document and validated with the schemas.

“ASC X12 TR3 Schemas are the only schemas authorized as derivative products of ASC X12 Technical Reports. They ease content integration into and out of back-end systems while promoting standardized XML for this set of HIPAA mandated transactions,” said Cathy Sheppard, Chair, ASC X12.

ASC X12 TR3 Schemas are licensed for internal use or for redistribution in vendor products. Applicable errata will be incorporated into each ASC X12 TR3 Schema, and a new version made available to purchasers at no additional cost, once the errata is mandated under HIPAA. Each schema package also includes the ASC X12 Technical Report Type 2, Constructing XML Schema Definition Element Names from ASC X12 Metadata.

For more information and to purchase ASC X12 TR3 Schemas, visit ASC X12’s On-Line Store – 005010 HIPAA Implementation Guides.

About ASC X12
ASC X12, chartered by the American National Standards Institute (ANSI) in 1979, develops EDI standards and documents for national and global markets. With more than 315 X12 EDI standards and increasing X12 XML schemas, ASC X12 enhances business processes, reduces costs and expands organizational reach. Members include standards experts from health care, insurance, transportation, finance, government, supply chain and other industries.

HOUSTON, TX–(Marketwire – October 14, 2010) –  Velocity Express today announced that Gerald T. Vento has been named Executive Chairman of the Houston, TX-based national logistics and transportation company.

“Velocity partners with its customers to deliver cost effective solutions. We have a strong balance sheet, better technology, national and regional networks and dedicated employees that strategically position us for success,” said Gerald Vento.

“Vento brings laser focus to the business, and as a Velocity customer, we welcome his addition to the company,” said Gough Grubbs, Senior Vice President, Logistics and Distribution, Stage Stores regarding the announcement.

“Stage Stores relies on Velocity to replenish 786 stores weekly through its national network, and Vento’s involvement this year has contributed to improved quality and consistency across Velocity’s complex network operations,” Grubbs added.

Vento brings years of extensive business growth experience to Velocity Express. Vento founded Telecorp PCS, serving as Chairman and CEO, and grew the wireless start-up venture to become a giant company in the mobile telecom business. Within six years after its launch, Telecorp’s annual revenues grew to more than $1.1 billion, and in 2002, Telecorp was sold to ATT Wireless for $5.7 billion.

“Gerald has an extraordinary talent set to guide Velocity’s strategic direction. We are fortunate to have Vento join Velocity,” said Jose Gordo, Managing Director of ComVest, a majority owner of Velocity Express and a leading private investment firm focused on middle market companies. Since 1988, ComVest has invested more than $2 billion of capital in more than 200 public and private companies.

About ComVest
The ComVest Group is a leading private investment firm focused on providing debt and equity solutions to lower middle-market companies with enterprise values of less than $350 million. With extensive financial resources and a broad network of industry experts, ComVest can offer companies total financial sponsorship, critical strategic support, and business development assistance.

About Stage Stores
Stage Stores, Inc. brings nationally recognized brand name apparel, accessories, cosmetics and footwear for the entire family to small and mid-size towns and communities through 787 stores located in 39 states. The Company operates its stores under the five names of Bealls, Goody’s, Palais Royal, Peebles and Stage. For more information about Stage Stores, visit the Company’s web site at www.stagestoresinc.com.

About Velocity Express
Velocity Express operates more than 80 strategically located warehouses and terminal facilities where customers’ packages are sorted, tracked, routed, and delivered. Velocity Express uses a qualified network of independent, licensed drivers who are aligned with the company’s safety and customer service policies. Privately held, Velocity Express is headquartered in Houston, TX.

Additional information about Velocity Express is available www.velocityexpress.com.

SAN JOSE, CA–(Marketwire – October 14, 2010) –  AmbiCom Holdings, Inc. (OTCBB: ABHI) today announced that it has signed a Letter of Intent with one of the world’s largest home care device manufacturers to develop the WiFi solution for their product lines that include blood pressure monitors and healthcare products for home and professional use. Ambicom expects to start generating revenue from this association by the first quarter of 2011 and also believes that this letter of intent can potentially bring significant revenue opportunities for the Company. Further information and details will be forthcoming later this year.

About AmbiCom

AmbiCom is headquartered in San Jose, California, and is a leading designer and developer of wireless products focusing on the wireless medical industry. The Company’s wireless modules and devices are based on the Company’s innovative application software for both Wi-Fi and Bluetooth technologies. AmbiCom is committed to wireless design and development of software and hardware and is bringing new and innovative products to the wireless medical markets and other sectors. The Company plans to grow organically, and to augment that growth by selectively acquiring complementary products and technologies via acquisition opportunities deemed to be of strategic value.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements including, but not limited to, our ability to maintain our website and associated computer systems, our ability to generate sufficient operating cash flow, and general economic conditions. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with the Securities and Exchange Commission, including those risks set forth in the Company’s Current Report on Form 8-K filed on January 15, 2010, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

JERICHO, NY–(Marketwire – October 14, 2010) – SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. (“TRDX” or the “Company”) (PINKSHEETS: TRDX) today announces that it has entered into discussion to acquire the exclusive rights to Eco-tabs, an innovative environmental product (www.eco-tabs.com).

Eco-tabs™ are patent pending, multifunctional tablets engineered to oxygenate wastewater, remove hydrogen sulfide odors, prevent corrosion, and initiate aerobic biological breakdown of organic sludge, including natural oils and grease.

The Company expects discussions to continue advancing towards a transaction in the near term.

Dr. Stahl, CEO of TRDX, commented: “We have a lot a belief in the global sales potential of Eco-tabs. I look forward to completing the next steps with them.”

About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)
SciMeDent (www.scimedenthealth.com) is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.

Cautionary Statement Regarding Forward-Looking Statements

A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological or industry changes and uncertainties related to the development of the Company’s business model. The actual results the Company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.